Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer

doi:10.3969/j.issn.1673-8640.2023.07.003

Abstract

Abstract:

Objective To investigate the relationship between soluble growth stimulating gene 2（sST2） protein and clinicopathological features and prognosis in patients with colorectal cancer. Methods A total of 101 patients diagnosed with colorectal cancer in Hai'an Hospital of Nantong University from May 2017 to May 2020 were enrolled，and serum sST2 level was determined. Clinical data and clinical laboratory determination results were collected. The optimal cut-off value of sST2 for patient prognosis（death） was evaluated by receiver operating characteristic（ROC）curve. Patient survival state was evaluated by Kaplan-Meier survival curve and Log-rank χ² test. Risk factors affecting overall survival（OS）were assessed using Cox proportional hazard regression analysis. Results The optimal cut-off value for sST2 was 459 pg/mL. The patients were classified into high sST2 group（>459 pg/mL）and low sST2 group（≤459 pg/mL）. Compared with low sST2 group，age，the proportion of Eastern Cooperative Oncology Group（ECOG） score ≥1 and the proportion of TNM stage Ⅲ in high sST2 group were increased（P<0.05），and the hemoglobin（Hb） level and tumor differentiation degree were decreased（P<0.05）. Kaplan-Meier survival curve indicated that the OS of high sST2 group was lower than that of low sST2 group（ Log-rank χ²=27.01，P<0.001）. Multivariate Cox proportional hazard regression analysis showed that ECOG score，TNM stage Ⅱ，TNM stage Ⅲ，moderate to poor tumor differentiation and sST2>459 pg/mL were associated with short OS [hazard ratios（HR） were 1.99，2.32，4.09，1.39，1.59，95% confidence interval（CI）1.23-3.01，1.64-4.32，2.32-8.32，1.03-2.00，1.21-2.08，P<0.05]. Conclusions High sST2 level promotes the progression of colorectal cancer and serves as an independent risk factor for poor prognosis. It can be potentially applied for the evaluation of patient prognosis.

Key words: Growth stimulating gene 2 protein, Colorectal cancer, Clinicopathological feature, Overall survival

CLC Number:

R446.1

ZHU Rixiang, YIN Jie. Relationship between soluble growth stimulating gene 2 protein and clinicopathological features and prognosis in patients with colorectal cancer[J]. Laboratory Medicine, 2023, 38(7): 629-633.

Figures/Tables 4

References 18

[1]	ARAGHI M, SOERJOMATARAM I, JENKINS M, et al. Global trends in colorectal cancer mortality:projections to the year 2035[J]. Int J Cancer, 2019, 144(12):2992-3000. DOI URL
[2]	OGUNWOBI O O, MAHMOOD F, AKINGBOYE A. Biomarkers in colorectal cancer:current research and future prospects[J]. Int J Mol Sci, 2020, 21(15):5311. DOI URL
[3]	VEREMEYKO T, YUNG A W Y, ANTHONY D C, et al. Early growth response gene-2 is essential for M1 and M2 macrophage activation and plasticity by modulation of the transcription factor cebpβ[J]. Front Immunol, 2018, 9:2515. DOI PMID
[4]	SUN Y, PAVEY H, WILKINSON I, et al. Role of the IL-33/ST2 axis in cardiovascular disease:a systematic review and meta-analysis[J]. PLoS One, 2021, 16(11):e0259026. DOI URL
[5]	CHANG C P, HU M H, HSIAO Y P, et al. ST2 signaling in the tumor microenvironment[J]. Adv Exp Med Biol, 2020, 1240:83-93.
[6]	PUSCEDDU I, DIEPLINGER B, MUELLER T. ST2 and the ST2/IL-33 signalling pathway-biochemistry and pathophysiology in animal models and humans[J]. Clin Chim Acta, 2019, 495:493-500. DOI PMID
[7]	GRIESENAUER B, PACZESNY S. The ST2/IL-33 axis in immune cells during inflammatory diseases[J]. Front Immunol, 2017, 8:475. DOI PMID
[8]	WANG J, HE M, LI H, et al. Soluble ST2 is a sensitive and specific biomarker for fulminant myocarditis[J]. J Am Heart Assoc, 2022, 11(7):e024417. DOI URL
[9]	KRITTAYAPHONG R, PUMPRUEG S, SAIRAT P. Soluble ST2 in the prediction of heart failure and death in patients with atrial fibrillation[J]. Clin Cardiol, 2022, 45(4):447-456. DOI PMID
[10]	燕亚茹, 谭鹤, 豆书梅, 等. 可溶性ST2在心力衰竭伴肾功能不全患者中的应用价值[J]. 中国心血管杂志, 2018, 23(6):481-485.
[11]	BERGIS D, KASSIS V, RADEKE H H. High plasma sST2 levels in gastric cancer and their association with metastatic disease[J]. Cancer Biomark, 2016, 16(1):117-125. DOI PMID
[12]	KIELER M, UNSELD M, WOJTA J, et al. Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy[J]. Med Oncol, 2018, 36(1):1. DOI PMID
[13]	LU D P, ZHOU X Y, YAO L T, et al. Serum soluble ST2 is associated with ER-positive breast cancer[J]. BMC Cancer, 2014, 14:198. DOI URL
[14]	CUI G, YUAN A, LI Z, et al. ST2 and regulatory T cells in the colorectal adenoma/carcinoma microenvironment:implications for diseases progression and prognosis[J]. Sci Rep, 2020, 10(1):5892. DOI
[15]	LANDSKRON G, DE LA FUENTE LÓPEZ M, DUBOIS-CAMACHO K, et al. Interleukin 33/ST2 axis components are associated to desmoplasia,a metastasis-related factor in colorectal cancer[J]. Front Immunol, 2019, 10:1394. DOI URL
[16]	AKIMOTO M, MARUYAMA R, TAKAMARU H, et al. Soluble IL-33 receptor sST2 inhibits colorectal cancer malignant growth by modifying the tumour microenvironment[J]. Nat Commun, 2016, 7:13589. DOI PMID
[17]	TOMINAGA S I, OHTA S, TAGO K. Soluble form of the ST2 gene product exhibits growth promoting activity in NIH-3T3 cells[J]. Biochem Biophys Rep, 2015, 5:8-15.
[18]	李东. 恶性胸水中sST2、Fascin含量与癌细胞恶性增殖、侵袭的相关性研究[J]. 海南医学院学报, 2018, 24(3):369-372.

组别	例数	年龄/岁	性别		高血压史/ [例（%）]	糖尿病史/ [例（%）]	饮酒史/ [例（%）]	吸烟史/ [例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	高血压史/ [例（%）]	糖尿病史/ [例（%）]	饮酒史/ [例（%）]	吸烟史/ [例（%）]
sST2高水平组	36	65.94±6.52	21（58.33）	15（41.67）	11（30.56）	8（22.22）	12（33.33）	7（19.44）
sST2低水平组	65	59.95±6.24	43（66.15）	22（33.85）	17（26.15）	7（10.77）	22（33.85）	20（30.77）
统计值		4.55	0.61		0.27	2.51	0.01	1.41
P值		<0.001	0.430		0.600	0.110	0.990	0.230

组别	例数	年龄/岁	性别		高血压史/ [例（%）]	糖尿病史/ [例（%）]	饮酒史/ [例（%）]	吸烟史/ [例（%）]
组别	例数	年龄/岁	男/[例（%）]	女/[例（%）]	高血压史/ [例（%）]	糖尿病史/ [例（%）]	饮酒史/ [例（%）]	吸烟史/ [例（%）]
sST2高水平组	36	65.94±6.52	21（58.33）	15（41.67）	11（30.56）	8（22.22）	12（33.33）	7（19.44）
sST2低水平组	65	59.95±6.24	43（66.15）	22（33.85）	17（26.15）	7（10.77）	22（33.85）	20（30.77）
统计值		4.55	0.61		0.27	2.51	0.01	1.41
P值		<0.001	0.430		0.600	0.110	0.990	0.230

指标	HR值（95%CI）	P值
年龄（≥60与 <60岁）	1.03（0.90~1.21）	0.670
ECOG评分（≥1分与0分）	1.99（1.23~3.01）	<0.001
Hb（<120 g/L与≥120 g/L）	1.08（0.54~2.00）	0.520
TNM分期
Ⅱ期与Ⅰ期	2.32（1.64~4.32）	<0.001
Ⅲ期与Ⅰ期	4.09（2.32~8.32）	0.008
肿瘤分化程度（中低分化与高分化）	1.39（1.03~2.00）	0.030
sST2（>459 pg/mL与≤459 pg/mL）	1.59（1.21~2.08）	0.010

指标	HR值（95%CI）	P值
年龄（≥60与 <60岁）	1.03（0.90~1.21）	0.670
ECOG评分（≥1分与0分）	1.99（1.23~3.01）	<0.001
Hb（<120 g/L与≥120 g/L）	1.08（0.54~2.00）	0.520
TNM分期
Ⅱ期与Ⅰ期	2.32（1.64~4.32）	<0.001
Ⅲ期与Ⅰ期	4.09（2.32~8.32）	0.008
肿瘤分化程度（中低分化与高分化）	1.39（1.03~2.00）	0.030
sST2（>459 pg/mL与≤459 pg/mL）	1.59（1.21~2.08）	0.010